GlassScriptPhysician profile
Richard S Han
NPI 1821061466
$76,316.79
in general payments reported to CMS, 2019-2025
54 companies · $3,105 in 2025
The $3,105 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $6,395 · 2021: $7,450 · 2022: $25K · 2023: $15K · 2024: $5,156 · 2025: $3,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $8,941 · Travel and Lodging: $744 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,822.50 |
| Food and Beverage | $8,941.43 |
| Travel and Lodging | $743.66 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $38,232.65 | 2019-2025 | Repatha, Evenity, Otezla |
| Janssen Pharmaceuticals, INC | $13,926.15 | 2019-2023 | Xarelto |
| Abbvie INC. | $3,146.54 | 2020-2025 | |
| Idorsia Pharmaceuticals US INC | $2,266.70 | 2022-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,709.72 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,396.14 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Merz North America, INC. | $1,186.94 | 2019-2022 | |
| Gilead Sciences, INC. | $1,045.84 | 2019-2025 | |
| Allergan, INC. | $1,035.60 | 2019-2022 | |
| Glaxosmithkline, LLC. | $998.06 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $885.60 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $877.56 | 2019-2025 | Mounjaro, Zepbound, Lyumjev |
| Amarin Pharma, INC. | $793.80 | 2019-2022 | |
| Pfizer INC. | $703.83 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $701.35 | 2022-2025 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $660.99 | 2021-2024 | Dexcom G6 Transmitter |
| Stryker Corporation | $595.48 | 2025 | Blueprint Patient Specific Instrumentation |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $580.95 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $544.58 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $540.21 | 2019-2024 | Linzess |
| Merck Sharp & Dohme LLC | $471.77 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Radius Health, INC. | $412.50 | 2019-2025 | Tymlos |
| Scilex Pharmaceuticals INC. | $396.45 | 2019-2024 | Ztlido |
| Ardelyx, INC. | $396.24 | 2024-2025 | Ibsrela |
| Esperion Therapeutics, INC. | $356.93 | 2020-2023 | Nexletol |
| Vivus LLC | $303.11 | 2021-2025 | Qsymia, Pancreaze |
| Astellas Pharma US INC | $239.21 | 2021-2025 | Veozah, Myrbetriq |
| Medicure Pharma INC. | $212.70 | 2020 | |
| Nestle Healthcare Nutrition INC. | $211.41 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $208.80 | 2019-2020 | |
| Galderma Laboratories, L.P. | $175.36 | 2019-2024 | |
| Eisai INC. | $130.99 | 2020-2024 | |
| Sumitomo Pharma America, INC. | $118.84 | 2024-2025 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $113.22 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $75.48 | 2023-2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $71.20 | 2019-2024 | Livalo, Zoryve, Seglentis |
| Abiomed | $65.71 | 2023-2024 | Impella |
| Ibsa Pharma INC. | $62.94 | 2023 | Tirosint, Licart |
| Sanofi-Aventis U.S. LLC | $58.59 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $57.09 | 2025 | Vowst, Zenpep |
| Bioventus LLC | $47.17 | 2019 | |
| Exact Sciences Corporation | $46.17 | 2024-2025 | Cologuard Collection Kit |
| Seqirus USA INC | $41.00 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $31.70 | 2020-2021 | |
| Orphalan INC | $30.30 | 2024 | Cuvrior |
| Biohaven Pharmaceutical Holding Company LTD. | $23.92 | 2022 | |
| Abbott Laboratories | $23.16 | 2025 | Freestyle Libre 3 |
| Optos, INC. | $20.19 | 2020 | |
| Endogastric Solutions, INC | $19.71 | 2020 | |
| Horizon Therapeutics Plc | $19.62 | 2021 | |
| Bausch Health US, LLC | $16.64 | 2021 | |
| Progenics Pharmaceuticals, INC. | $16.03 | 2024 | |
| Edwards Lifesciences Corporation | $13.43 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Forte Bio-Pharma LLC | $0.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.